Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase1/2 Study of Vaccination With CDCA1 Derived Epitope Peptide for HLA-A24-positive Patients With Advanced Prostate Cancer

NCT01225471 is registered in ClinicalTrials.gov with Iwate Medical University as lead sponsor.

NCT NCT01225471
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01225471 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase1/2 Study of Vaccination With CDCA1 Derived Epitope Peptide for HLA-A24-positive Patients With Advanced Prostate Cancer
Lead sponsor
Iwate Medical University
Phase
Phase 1/2
Overall status
Unknown status
Start date
June 30, 2009
Completion date
May 31, 2012
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer